<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34678870</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>42</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e27421</StartPage><MedlinePgn>e27421</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e27421</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000027421</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The primary objective was to demonstrate the safety and tolerability of monoclonal antibody against CD14 (IC14) (atibuclimab) in amyotrophic lateral sclerosis patients. The secondary objectives were pharmacokinetics, pharmacodynamics, and preliminary effects on disease status and biomarkers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label, dose-escalation trial, IC14 was administered at 2&#x200a;mg/kg intravenous (IV) followed by 1&#x200a;mg/kg/d IV &#xd7; 3 (n&#x200a;=&#x200a;3) and in subsequent patients at 4&#x200a;mg/kg IV followed by 2&#x200a;mg/kg/d IV &#xd7; 3 (n&#x200a;=&#x200a;7) (NCT03487263). Disease status was measured using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, forced vital capacity, sniff nasal pressure, Edinburgh Cognitive and Behavioural ALS Screen, and Revised ALS-Specific Quality-of-Life Score. Disease biomarkers included cerebrospinal fluid and serum levels of neurofilament light chain (NfL) and urinary p75 neurotrophin receptor.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">IC14 was safe and well tolerated. No antidrug antibodies were detected. The drug target saturation of monocyte CD14 receptors was rapid and sustained through day 8. There was no significant change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, forced vital capacity, sniff nasal pressure, or Revised ALS-Specific Quality-of-Life Score following a single cycle of treatment. Cerebrospinal fluid NfL levels decreased in 6 of 9 patients sampled with declines of 15% to 40% between baseline (not significant [ns]) and day 8 in 3 patients. Serum NfL modestly decreased in 5 of 10 patients (ns) at day 8 and was sustained in 4 (4%-37%, ns) over 33&#x200a;days of follow up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IC14 quickly and durably saturated its target in all patients. This study demonstrated safety and tolerability in patients with amyotrophic lateral sclerosis. Even though only a single cycle of treatment was given, there were promising beneficial trends in the neurofilament light chain, a disease biomarker. The emerging understanding of the role of systemic inflammation in neurodegenerative diseases, and the potential for IC14 to serve as a safe, potent, and broad-spectrum inhibitor of immune dysregulation merits further clinical study.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT03487263.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Royal Brisbane &amp; Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, Centre for Clinical Research, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agosti</LastName><ForeName>Jan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-4952-3297</Identifier><AffiliationInfo><Affiliation>Implicit Bioscience, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implicit Bioscience, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCombe</LastName><ForeName>Pamela A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Royal Brisbane &amp; Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Queensland, Centre for Clinical Research, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorpe</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Royal Brisbane &amp; Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heggie</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Brisbane &amp; Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heshmat</LastName><ForeName>Saman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Brisbane &amp; Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appleby</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Implicit Bioscience, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implicit Bioscience, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegelaar</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Implicit Bioscience, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implicit Bioscience, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Implicit Bioscience, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implicit Bioscience, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redlich</LastName><ForeName>Garry L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Implicit Bioscience, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implicit Bioscience, Brisbane, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03487263</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ID:03_TRG_2017_Henderson.</GrantID><Agency>FightMND</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000719996">atibuclimab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors RDH, PAM, KT, SH and SH reported no conflicts of interest. JMA was a consultant for Implicit Bioscience. MWA, BWZ, DTC, and GLR were employed by Implicit Bioscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34678870</ArticleId><ArticleId IdType="pmc">PMC8542123</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000027421</ArticleId><ArticleId IdType="pii">00005792-202110220-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol 2019;18:211&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Janova H, B&#xf6;ttcher C, Holtman IR, et al. . CD14 is a key organizer of microglial responses to CNS infection and injury. Glia 2016;64:635&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26683584</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. . Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep 2020;10:01&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilarregui JM, Van Beelen AJ, Fehres CM, Bruijns SCM, Garc&#xed;a-Vallejo JJ, Van Kooyk Y. New roles for CD14 and IL-&#x3b2; linking inflammatory dendritic cells to IL-17 production in memory CD4+ T cells. Immunol Cell Biol 2016;94:907&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">27550748</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med 2011;11:246&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers D, Appel S. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2013;8:888&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff NP, Appel SH. The immune system continues to knock at the ALS door. Neuromuscul Disord 2016;26:335&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133660</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtelle T, Pribble J. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Int Endotoxin Innate Immun 2001;7:310&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11717588</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart K, Gl&#xfc;ck T, Ligtenberg J, et al. . CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004;32:1100&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190957</ArticleId></ArticleIdList></Reference><Reference><Citation>Spek CA, Verbon A, Aberson H, et al. . Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J Clin Immunol 2003;23:132&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757265</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbon A, Dekkers PEP, ten Hove T, et al. . IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001;166:3599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207321</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, De Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol 2012;69:1410&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al. . Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders. Amyotroph Lateral Scler Front Degener 2015; 16:172-9.Abrahams S, Bak T. Edinburgh Cognitive and Behavioural ALS Screen - ECAS English version 2013.2013;Available from: https://www.era.lib.ed.ac.uk/handle/1842/6592</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics 2015;12:394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404446</ArticleId><ArticleId IdType="pubmed">25502407</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgoise SH, Walsh SM, Stephens MA, Brothers A, Simmons Z. The ALS Specific Quality of Life-Revised (ALSSQOL-R) User's Guide. 2011;1&#x2013;63. Version 1.</Citation></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, MacDonald-Wallis C, Gray E, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;90:157&#x2013;64. [cited 2018 Nov 19]; jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. . Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 2017;88:1137&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis. Muscle Nerve 2009;39:858&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19382169</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C, Neuwirth C, Weber M. Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): lack of practice effect in ALS patients? Amyotroph Lateral Scler Front Degener 2017;18:202&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165766</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol 2020;11:01&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. . Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol 2017;74:677&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009;187:761&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Chattopadhay M, La Cava A, et al. . IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation 2010;7:01&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, et al. . Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand 2010;122:425&#x2013;9. [cited 2016 Sep 23];122(6):425-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, Moumen A, Sazdovitch V, Seilhean D, Meininger V, Raoul C. Elevated levels of IFN&#x3b3; and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012;19:752&#x2013;9. [cited 2017 Jan 18];19(5):752-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22221541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez HR, Escamilla-Oca&#xf1;as CE, Tenorio-Pedraza JM, et al. . Altered CSF cytokine network in amyotrophic lateral sclerosis patients: a pathway-based statistical analysis. Cytokine 2017;90:01&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27741429</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Iyer AM, Spliet WGM, et al. . Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011;179:233&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Siklos L, et al. . Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004;55:221&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. . Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et al. . Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol NeuroInflamm 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, et al. . Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011;134(Pt 5):1293&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KHG. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011;11:807&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22094985</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves M, Fiala M, Dinglasan L, et al. . Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler 2004;5:213&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;v&#xea;que M, Jeune KS Le, Jouneau S, et al. . Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in inflammatory cytokine/chemokine production. FASEB J 2017;31:1891&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">28122919</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>